Skip to main content

Table 1 Basic characteristics of the study cohort and fertility treatment

From: Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?

 

n = 53

Age

34.5 ± 5.5

BMI

22.7 ± 5.9

FSH

7.4 (6,9)

LH

4.7 (3,7)

FSH to LH

1.7 ± 0.8

Infertility treatment indication

 Fertility preservation

21 (39.6)

 Poor ovarian reserve

3 (5.6)

 PGT

14 (26.4)

 Male factor

7 (13.2)

 Tubal factor

2 (3.7)

 Unexplained

4 (7.5)

 Other

2 (3.7)

Final follicular maturation

 hCG

7 (13.2)

 GnRH agonist

32 (60.3)

 Dual triggera

14 (26.4)

Pergoveris first cycle

18 (35.8)

  1. Data are presented as mean ± SD, median (intra-quartile range) or numbers and percentage
  2. aDual trigger- hCG + GnRH agonist